

Subject index

Volume 185 (2006)

- Adherence **185**, 394
ADMA **185**, 313
Aerobic exercise **185**, 65
Aerobic power **185**, 381
Ageing **185**, 183, 191
Angina **185**, 375
Angiography **185**, 114
Animal model **185**, 246
Anticardiolipin antibodies **185**, 246
Antioxidant **185**, 191
Antiretroviral therapy **185**, 361
Anxiety **185**, 320
Aortic arch **185**, 159
Aortic valve calcification **185**, 406
APOA5 **185**, 143, 353, 433
APOC3 **185**, 353
Apolipoprotein A1 **185**, 65, 127
Apolipoprotein A-V **185**, 353
Apolipoprotein B **185**, 21, 307
Apolipoprotein B48 **185**, 438
Apolipoprotein C-III **185**, 353
Apolipoprotein **185**, 78, 87
Arginine **185**, 271
Arterial stiffness **185**, 368
Asymmetric dimethylarginine **185**, 271, 421
Atherogenesis **185**, 1
Atherosclerosis **185**, 39, 70, 114, 165, 219, 254, 271, 290, 307, 320, 331, 361, 368, 406

Bile acid sequestrants **185**, 327
Blood platelets **185**, 173
Blood pressure **185**, 340
B-mode ultrasonography **185**, 159

Calcium **185**, 290
Campesterol **185**, 206
Cardiovascular disease prevention **185**, 381
Cardiovascular disease **185**, 1, 12, 58, 78, 173, 361, 438
Cardiovascular function and structure **185**, 227
Cardiovascular risk **185**, 227, 368
Cardiovascular **185**, 421
Carotid artery **185**, 108, 121
Carotid intima-media thickness **185**, 307
Cell adhesion molecules **185**, 150
Cerebrovascular events **185**, 121
CHD risk factors **185**, 297
Chemotaxis **185**, 331
Cholesterol **185**, 78, 206, 278, 438
Cholesteryl ester transfer protein gene polymorphism **185**, 121
Cholesteryl ester **185**, 87
Cholesterol ester transfer protein **185**, 97
Chronic stable angina **185**, 137
Coagulation **185**, 240, 320
Cohort studies **185**, 388
Cohort **185**, 58
Colesevelam HCl **185**, 327
Collagen **185**, 173
Computed tomography **185**, 394
Coronary artery calcification **185**, 177, 340, 394
Coronary artery calcium **185**, 177
Coronary artery disease **185**, 127, 137, 159, 340, 433
Coronary disease **185**, 114, 143, 177
C-reactive protein **185**, 137, 307, 347
Cystatin-C **185**, 375

Diabetes mellitus **185**, 173
Diet **185**, 297
Dyslipidemia **185**, 58

Electron beam **185**, 394
Endothelial cells **185**, 47
Endothelial dysfunction **185**, 313
Endothelial function **185**, 39
Endothelial-derived relaxation **185**, 47
Endothelium **185**, 240, 290, 368
Endurance training **185**, 201
Epidemiology **185**, 78, 375
Erectile dysfunction **185**, 421
Estradiol ester **185**, 264
Estrogen receptor genetic polymorphisms **185**, 210
Estrogen **185**, 264
Exercise test **185**, 381
Exercise **185**, 87, 426
Extracellular matrix **185**, 165

Familial hypercholesterolemia **185**, 307
Familial LCAT deficiency **185**, 413
Family study **185**, 150
Femoral artery **185**, 201
French Canadian population **185**, 127

Gene expression **185**, 47
Gene mutation **185**, 127
General population **185**, 177
General practitioners **185**, 58
Genetic correlation **185**, 150
Genetic epidemiology **185**, 426
Genetic linkage **185**, 340

- Genetic variation **185**, 433
 Genetics **185**, 78
 Glucose intolerance **185**, 297
 Glutathione and thioredoxin systems **185**, 282
 GTPase **185**, 219
 Guidelines **185**, 12, 58
- Haplotypes **185**, 97
 HDL cholesterol **185**, 183
 HDL **185**, 191, 438
 HDL3 **185**, 264
 Hepatic lipase gene polymorphism **185**, 121
 Heritability **185**, 150
 High density lipoprotein **185**, 65
 High-density lipoprotein deficiency **185**, 127
 High-density lipoprotein **185**, 78
 High-density lipoprotein-cholesterol **185**, 143, 340,
 Highly active antiretroviral therapy **185**, 1
 HIV **185**, 361
 HMG-CoA reductase **185**, 21
 Homocysteine **185**, 278
 Hormone therapy **185**, 347
 HSP70 **185**, 32
 Human immunodeficiency virus **185**, 1
 Hydroxychloroquine **185**, 406
 Hydroxymethylglutaryl-CoA reductase inhibitors **185**, 97
 Hypercholesterolemia familial **185**, 97
 Hyperglycemia **185**, 70
 Hyperinsulinemia **185**, 47
 Hyperlipidemia **185**, 12
 Hyperoxia **185**, 254
 Hypertriglyceridaemia **185**, 353
 Hypertriglyceridemia **185**, 264
 Hypo-alpha lipoproteinemia **185**, 127, 413
 Hypoxia **185**, 254, 290
- Indian **185**, 297
 Inflammation **185**, 39, 114, 137, 240, 320, 331, 381
 Inflammatory markers **185**, 150
 Insulin receptor **185**, 21
 Insulin resistance **185**, 21, 227
 Insulin treatment **185**, 47
 Insulin **185**, 438
 Intercellular adhesion molecule **185**, 347
 Interleukin-6 **185**, 347
 Intima-media thickness **185**, 121, 159, 361, 388
- Lathosterol **185**, 206
 LCAT gene mutation **185**, 413
 LDL cholesterol **185**, 183
 LDL particle number **185**, 327
 LDL size **185**, 327
 LDL **185**, 438
 Lecithin:cholesterol acyltransferase **185**, 264
 Leukocytes **185**, 331
 Lipase **185**, 78
 Lipid peroxidation **185**, 191, 254
 Lipid subclasses **185**, 210
 Lipids obesity **185**, 426
 Lipids **185**, 32, 173
 Lipoprotein particle size **185**, 210
 Lipoprotein subclasses **185**, 327
 Lipoprotein **185**, 219, 264
 Longitudinal study **185**, 183
 Low-density lipoprotein **185**, 121
 Lymphotoxin alpha **185**, 400
- Macrophage **185**, 282
 Matrix metalloproteinases **185**, 165, 347
 MDR **185**, 97
 Metabolism **185**, 206
 Microsomal triglyceride transfer protein **185**, 21
 Mitral annular calcification **185**, 406
 Mortality **185**, 406
 Multivariate **185**, 340
 Myocardial fibrosis **185**, 278
 Myocardial infarction **185**, 1, 375, 400
- NAD(P)H-oxidase **185**, 219
 Nitric oxide **185**, 246, 368
 Non-nucleoside reverse transcriptase inhibitors **185**, 1
 NO-synthase **185**, 219
- Obesity follow-up **185**, 388
 Obesity **185**, 137, 340, 381
 Oxidation **185**, 264
 Oxidative stress **185**, 219, 290, 331
 Oxidized LDL **185**, 282
 Oxidized low-density lipoprotein **185**, 32, 307
 Oxygen free radicals **185**, 191
- Paraoxonase **185**, 191
 Pharmacogenetics **185**, 97
 Physical activity **185**, 297, 381
 Plaque disruption **185**, 165
 Plaque **185**, 114
 Platelet activation **185**, 173
 Polycystic ovary syndrome **185**, 227
 Polymorphisms **185**, 143, 400, 433
 Polyphenols **185**, 438
 Postmenopausal women **185**, 438
 Postprandial lipemia **185**, 313
 Postprandial **185**, 87
 Prevention **185**, 177
 Primary prevention **185**, 58
 Prognosis **185**, 400
 Proliferation **185**, 219
 Protease inhibitors **185**, 1
 Protein **185**, 313
 Psychological **185**, 320
 Pulse pressure **185**, 340
 Pulse wave analysis **185**, 368
- Quantitative trait loci **185**, 426
- RAGE **185**, 70
 Receptors, Fc **185**, 173
 Red wine **185**, 438
 Remnant-like lipoprotein **185**, 87
 Restenosis **185**, 254
 RhoA **185**, 219
 Risk factors **185**, 12, 375, 421, 426
- Rosuvastatin **185**, 21
- Selectin **185**, 421
 Shear stress **185**, 108
 Signal transduction **185**, 240
 Sildenafil **185**, 421
 Single nucleotide polymorphism **185**, 65, 97
 SLICC/ACR damage index **185**, 406
 Smoking **185**, 183
 SREBF-1 **185**, 206
 Statin therapy **185**, 394
 Statins **185**, 12, 240, 290, 307, 331

- Streptozotocin **185**, 47
Stroke **185**, 108, 271
Subfraction **185**, 65
Sulfhydryl groups **185**, 191
Synthesis **185**, 206
Syrian golden hamster **185**, 21
Systemic lupus erythematosus **185**, 406
- TIA **185**, 271
Tissue factor pathway inhibitor-2 **185**, 165
- Tissue inhibitor of metalloproteinases **185**, 165
Tobacco **185**, 201
Total cholesterol **185**, 183
Triglyceride **185**, 87, 143, 183, 433
Type 1 diabetes **185**, 47
Type 2 diabetes **185**, 70
- VLDL **185**, 87
- Women **185**, 210